↓ Skip to main content

Laetrile treatment for cancer

Overview of attention for article published in Cochrane database of systematic reviews, April 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
12 news outlets
blogs
5 blogs
twitter
44 tweeters
facebook
7 Facebook pages
wikipedia
5 Wikipedia pages
video
3 video uploaders

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Laetrile treatment for cancer
Published in
Cochrane database of systematic reviews, April 2015
DOI 10.1002/14651858.cd005476.pub4
Pubmed ID
Authors

Stefania Milazzo, Markus Horneber, Edzard Ernst

Abstract

Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, laetrile can be dangerous. To assess the alleged anti-cancer effect and possible adverse effects of laetrile and amygdalin. We searched the following databases: CENTRAL (2014, Issue 9); MEDLINE (1951-2014); EMBASE (1980-2014); AMED; Scirus; CINAHL (all from 1982-2015); CAMbase (from 1998-2015); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Randomized controlled trials (RCTs) and quasi-RCTs. We searched eight databases and two registers for studies testing laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. We located over 200 references, 63 were evaluated in the original review, 6 in the 2011 and none in this update. However, we did not identify any studies that met our inclusion criteria. The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.

Twitter Demographics

The data shown below were collected from the profiles of 44 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Australia 2 2%
South Africa 2 2%
United States 2 2%
Brazil 2 2%
Switzerland 1 <1%
Canada 1 <1%
Unknown 93 89%

Demographic breakdown

Readers by professional status Count As %
Unspecified 18 17%
Student > Master 16 15%
Student > Ph. D. Student 16 15%
Student > Bachelor 15 14%
Student > Postgraduate 11 10%
Other 29 28%
Readers by discipline Count As %
Medicine and Dentistry 49 47%
Unspecified 23 22%
Agricultural and Biological Sciences 8 8%
Biochemistry, Genetics and Molecular Biology 6 6%
Social Sciences 5 5%
Other 14 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 168. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2019.
All research outputs
#81,490
of 13,384,857 outputs
Outputs from Cochrane database of systematic reviews
#172
of 10,576 outputs
Outputs of similar age
#1,744
of 228,089 outputs
Outputs of similar age from Cochrane database of systematic reviews
#6
of 235 outputs
Altmetric has tracked 13,384,857 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,576 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,089 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.